Relationship between serum substance P levels and daytime sleepiness in obstructive sleep apnea syndrome

Chest

Volumn 131, Issue 5, 2007, Pages 1400-1405

  Ursavas, Ahmet ^a   Karadag, Mehmet ^a   Ilcol, Yesim Ozarda ^a   Burgazlioglu, Basak ^a   Ercan, Ilker ^a   Gozu, R Oktay ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Obstructive sleep apnea syndrome; Sleepiness; Substance P

Indexed keywords

SUBSTANCE P;

ADULT; APNEA; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DAYTIME SOMNOLENCE; FEMALE; HUMAN; HYPOXIA; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REM SLEEP; SCORING SYSTEM; SLEEP APNEA SYNDROME; SLOW WAVE SLEEP;

EID: 34248582390     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.06-2348     Document Type: Article

References (25)

1. ASDA-Diagnostic Classification Steering Committee. The international classification of sleep disorders: diagnostic and coding manual. 2nd ed. Lawrence, KS: Allen Press, 1997
2. Young T, Blustein J, Finn L, et al. Sleepiness, driving and accidents sleep-breathing disorders and motor vehicle accidents in a population based sample of employed adults. Sleep 1997; 20:608-613
3. Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365: 1046-1053
4. Bixler EO, Vgontzas AN, Lin H-M, et al. Prevalence of sleep disorders breathing in women: effects of gender. Am J Respir Crit Care Med 2001; 163:608-613
5. Sergeyev V, Hokfelt T, Hurd Y. Serotonin and substance P co-exist in dorsal raphe neurons of the human brain. Neuroreport 1999; 10:3967-3970
6. Murillo-Rodrigez E, Cabeza R, Mendez-Diaz L, et al. Anandamide-induced sleep is blocked by SR141716A, a CB1 receptor antagonist and by U73122, a phospholipase C inhibitor. Neuroreport 2001; 12:2131-2136
7. Russell IJ, Michalek JE, Vipraio GA, et al. Platelet 3H-imipraine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 1992; 19:104-109
8. Schwarz MJ, Spath M, Muller-Bardorff H, et al. Relationship of substance P, 5-hydroxidole acetic acid and tryptophan in serum fibromyalgia patients. Neurosci Lett 1999; 259:196-198
9. Vaeroy H, Helle R, Terenis L. Elevated CSF levels of substance P and high incidence of Raynaud's phenomenon in patients in fibromyalgia: new features for diagnosis. Pain 1988; 32:21-26
10. Rupniak NM, Kramer MS. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol Sci 1999; 20:485-490
11. Hecht K, Oehme P, Kolometsewa IA, et al. Effect of substance P analog on sleep deprivation. Acta Biol Med Ger 1980; 39:141-147
12. Nattie EE, Li A. Substance P-saporin lesion of neurons with NK1 receptors in one chemoreceptor site: in rats decreases ventilation and chemosensitivity. J Physiol 2002; 544:603-616
13. Lindefors N, Yamamoto Y, Pantaleo T, et al. In vivo release of substance P in the nucleus tractus solitarii increases during hypoxia. Neurosci Lett 1986; 69:94-97
14. Lieb K, Ahlvers K, Dancker K, et al. Effects of the neuropeptide substance P on the sleep, mood, and neuroendocrine measures in healthy young men. Neuropsychopharmacology 2002; 27:1041-1049
15. Zhang G, Wang L, Liu H, et al. Substance P promotes sleep in the ventrolateral preoptic area of rats. Brain Res 2004; 1028:225-232
16. Andersen ML, Nascimento DC, Machado RB, et al. Sleep disturbance by substance P in mice. Behav Brain Res 2006; 167:212-218
17. Ebner K, Singewald N. The role of substance P in stress and anxiety responses. Amino Acids 2006;31:251-272
18. Holmes A, Heilig M, Rupniak NM, et al. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci 2003; 24:580-588
19. Chappa AK, Audus KL, Lunte SM. Characteristics of substance P transport across the blood brain barrier. Pharm Res 2006; 23:1201-1208
20. Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998; 281:1640-1645
21. Bixler EO, Vgontzas AN, Lin HM, et al. Excessive daytime sleepiness in a general population sample: the role of sleep apnea, age, obesity, diabetes, and depression. J Clin Endocrinol Metab 2005; 90:4510-4515
22. Reishtein JL, Pack AI, Maislin G, et al. Sleepiness and relationships in obstructive sleep apnea. Issue Mental Health Nurs 2006; 27:319-330
23. Kapur VK, Baldwin CM, Resnick HE, et al. Sleepiness in patients with moderate to severe sleep-disordered breathing. Sleep 2005; 28:472-477
24. Gislason T, Hedner J, Terenius L, et al. Substance P, thyrotropin-releasing hormone, and monoamine metabolites in cerebrospinal fluid in sleep apnea. Am Rev Respir Dis 1992; 146:784-786
25. Strittmatter M, Isenberg E, Grauer MT, et al. CSF substance P somatostatin and monoaminergic transmitter metabolites in patients with narcolepsy. Neurosci Lett 1996; 218:99-102